Cargando…

Construction of Various γ34.5 Deleted Fluorescent-Expressing Oncolytic herpes Simplex type 1 (oHSV) for Generation and Isolation of HSV-Based Vectors

BACKGROUND: Oncolytic herpes simplex virus (oHSV)-based vectors lacking γ34.5 gene, are considered as ideal templates to construct efficient vectors for (targeted) cancer gene therapy. Herein, we reported the construction of three single/dually-flourescence labeled and γ34.5-deleted, recombinant HSV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdoli, Shahriyar, Roohvand, Farzin, Teimoori-Toolabi, Ladan, Shokrgozar, Mohammad Ali, Bahrololoumi, Mina, Azadmanesh, Kayhan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pasteur Institute 2017
Materias:	Full Length
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459936/ https://www.ncbi.nlm.nih.gov/pubmed/28525954 http://dx.doi.org/10.18869/acadpub.ibj.21.4.206

Ejemplares similares

Cytotoxic effect of dual fluorescent-labeled oncolytic herpes simplex virus type 1 on mouse tumorigenic cell lines
por: Abdoli, Shahriyar, et al.
Publicado: (2019)

The chicken chorioallantoic membrane model for isolation of CRISPR/cas9-based HSV-1 mutant expressing tumor suppressor p53
por: Kelishadi, Mishar, et al.
Publicado: (2023)

oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy
por: Sahu, Upasana, et al.
Publicado: (2023)

Chimeric HCMV/HSV-1 and Δγ(1)34.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory()()
por: Ghonime, Mohammed G., et al.
Publicado: (2017)

Cell type-specific response of colon cancer tumor cell lines to oncolytic HSV-1 virotherapy in hypoxia
por: Shayan, Sara, et al.
Publicado: (2022)

Developing oncolytic Herpes simplex virus type 1 through UL39 knockout by CRISPR-Cas9
por: Ebrahimi, Saeedeh, et al.
Publicado: (2020)

No Role of Herpes Simplex Virus Type 2 (HSV-2) Infection on HIV Progression in Naïve HIV Patients
por: Mohraz, Minoo, et al.
Publicado: (2018)

The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment
por: Uche, Ifeanyi Kingsley, et al.
Publicado: (2021)

Pneumomediastinum and Pneumothorax Associated with Herpes Simplex Virus (HSV) Pneumonia
por: López-Rivera, Fermín, et al.
Publicado: (2018)

Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses—Clearance and Biodistribution in Naïve and HSV-Preimmune Mice
por: Vannini, Andrea, et al.
Publicado: (2023)

Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment
por: Jackson, Joseph W., et al.
Publicado: (2021)

An Enterovirus-Like RNA Construct for Colon Cancer Suicide Gene Therapy
por: Rasekhian, Mahsa, et al.
Publicado: (2015)

A Replication-Defective Herpes Simplex Virus (HSV)-2 Vaccine, HSV529, is Safe and Well-Tolerated in Adults with or without HSV Infection and Induces Significant HSV-2-Specific Antibody Responses in HSV Seronegative Individuals
por: Dropulic, Lesia, et al.
Publicado: (2017)

1410. Neonatal Herpes Simplex Virus (HSV) Infection: Is It the Only Pathogen?
por: Dendi, Alvaro, et al.
Publicado: (2020)

Detection of circulating tumor cells using oHSV1‐hTERT‐GFP in lung cancer
por: Gao, Hongjun, et al.
Publicado: (2017)

esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation
por: Swanner, Jessica, et al.
Publicado: (2023)

Comparative Evaluation of AmpliVue HSV 1+2 Assay with ELVIS Culture for Detecting Herpes Simplex Virus 1 (HSV-1) and HSV-2 in Clinical Specimens
por: Granato, Paul A., et al.
Publicado: (2015)

Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses
por: Jafari, Mahdie, et al.
Publicado: (2022)

Herpes Simplex Virus Mistyping due to HSV-1 × HSV-2 Interspecies Recombination in Viral Gene Encoding Glycoprotein B
por: Casto, Amanda M., et al.
Publicado: (2020)

Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models
por: Braidwood, Lynne, et al.
Publicado: (2014)

STING Restricts oHSV Replication and Spread in Resistant MPNSTs but Is Dispensable for Basal IFN-Stimulated Gene Upregulation
por: Lee, Joel M., et al.
Publicado: (2019)

GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival
por: Sette, Paola, et al.
Publicado: (2019)

Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV
por: Vannini, Andrea, et al.
Publicado: (2021)

False Positive PCR for Herpes Simplex Virus (HSV) in Childhood CNS Infections
por: Sasan, M S
Publicado: (2012)

Oncolytic HSV: Underpinnings of Tumor Susceptibility
por: Kangas, Chase, et al.
Publicado: (2021)

Enhancement of Herpes Simplex Virus (HSV) Infection by Seminal Plasma and Semen Amyloids Implicates a New Target for the Prevention of HSV Infection
por: Torres, Lilith, et al.
Publicado: (2015)

Herpes simplex virus 2 (HSV-2) evolves faster in cell culture than HSV-1 by generating greater genetic diversity
por: López-Muñoz, Alberto Domingo, et al.
Publicado: (2021)

HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy
por: Li, H, et al.
Publicado: (2013)

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV
por: Gianni, Tatiana, et al.
Publicado: (2021)

IM-4 Impact of oHSV activated NOTCH signaling in tumor microenvironment and its impact on anti-tumor immunity
por: Yoshihiro, Otani, et al.
Publicado: (2021)

Effect of Copper Acyclovir Complexes on Herpes Simplex Virus Type 1 and Type 2 (HSV-1, HSV-2) Infection in Cultured Cells
por: Panteva, M., et al.
Publicado: (1998)

THE EFFECT OF GESTATIONAL AGE AND LABOR UPON INTRACELLULAR SURVIVAL OF HERPES SIMPLEX VIRUS (HSV)
por: Andersen, Richard D, et al.
Publicado: (1984)

Herpes simplex (HSV) viral load in bronchoalveolar lavage: risk factors and clinical outcome
por: Linssen, C.F.M., et al.
Publicado: (2006)

PTEN potentiation of oncolytic HSV therapy for glioblastoma
por: Migliarese, Christian, et al.
Publicado: (2023)

Expression of HSV-1 Receptors in EBV-Associated Lymphoproliferative Disease Determines Susceptibility to Oncolytic HSV
por: Wang, Pin-Yi, et al.
Publicado: (2012)

Correction: Effect of Copper Acyclovir Complexes on Herpes Simplex Virus Type 1 and Type 2 (HSV-1, HSV-2) Infection in Cultured Cells
por: Panteva, M., et al.
Publicado: (1998)

Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs
por: Brans, Richard, et al.
Publicado: (2010)

Circulating herpes simplex type 1 (HSV-1)-specific CD8(+ )T cells do not access HSV-1 latently infected trigeminal ganglia
por: Himmelein, Susanne, et al.
Publicado: (2011)

Herpes Simplex Virus 2 (HSV-2) Infected Cell Proteins Are among the Most Dominant Antigens of a Live-Attenuated HSV-2 Vaccine
por: Geltz, Joshua J., et al.
Publicado: (2015)

oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity
por: Zhang, Wen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nuao5ct1oqvo93cqb4crh74j2s